The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19
Status:
Recruiting
Trial end date:
2020-10-30
Target enrollment:
Participant gender:
Summary
This study aims to analyze the effectiveness and safety of Avigan® (favipiravir) compared to
Oseltamivir as an adjuvant therapy among adult COVID-19 patients. This study will be
conducted in a hospital setting, recruiting adult COVID-19 patients with mild, moderate, and
severe symptoms. Subjects will be randomly given Favipiravir or Oseltamivir as an adjuvant
therapy to standard COVID-19 treatment. Patients will be followed up for 21 days after the
first dose of intervention given. The primary outcomes of this study are the improvement of
radiology results and RT PCR negative conversion during follow up. The secondary outcomes are
adverse events, hospital length of stay (LOS), and Case fatality rate (CFR)